All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
In a letter to the editor of Blood published online in July ahead of print, Joseph M. Connors, of the British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, Canada, and colleagues presented five-year follow-up data on the use of Brentuximab Vedotin (BV) in combination with ABVD or AVD in a cohort of 51 previously untreated advanced stage classical Hodgkin Lymphoma patients. In the previously reported data set from this study it was concluded that the addition of BV to ABVD in HL patients resulted in ‘excessive pulmonary toxicity’ when compared to patients being treated with this combination, but without bleomycin2. A follow-up study was therefore instigated to determine the longer-term safety and efficacy data comparing BV with either ABVD or AVD.
In conclusion, the authors stated that the combination of AVD+BV is safe, and results in ‘excellent and durable control’ of cHL. The authors also state that the possible superiority of the combination of AVD+BV compared with ABVD alone is being assessed in the ECHELON trial.
Abstract: N/A
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox